NEU neuren pharmaceuticals limited

Ann: NNZ2566 Rationale in ASDs , page-4

  1. 11,715 Posts.
    lightbulb Created with Sketch. 1543

    Looks like there's another subtle link again with the work we are doing with Dr. Eric Hollander.

    Here's the presentation that Eric did a little over a year ago (see underlined below)...

    http://www.autismus-kongress.de/media/Vortraege_2012Praesentation_Autismus2012_Hollander.pdf

    Cell cycle – synapseopathy; dendritic sprouting; macrocephaly
    uPTEN, IGF-1, NNZ-2566 (ACE, Simons), oxytocin
    M-TOR – rapamycin, afinitor

    and

    These effects may be mediated by modulation of the PI3K-Akt-mToR pathway.

    and here is NEU's CA today.... that's the pathway Eric is referring to...

    IGF-1 and Glypromate is a natural growth factor that:
    o May act via the Akt-mToR pathway


    and

    Model for how serotonin and PI3K signaling
    pathways interact via SLca4 and Pten to influence
    brain size, sociability, PPI, perseverative
    behaviors (Page et al, 10.1073/pnas.0804428106)


    Here's a link to Dr. Eric Hollander and Dr. Mike Snape bio's....

    2012 International Autism Conference Speakers

    Regards,
    Tony

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$16.48
Change
-0.290(1.73%)
Mkt cap ! $2.076B
Open High Low Value Volume
$16.58 $16.74 $16.40 $9.107M 549.9K

Buyers (Bids)

No. Vol. Price($)
1 864 $16.43
 

Sellers (Offers)

Price($) Vol. No.
$16.50 1668 1
View Market Depth
Last trade - 16.10pm 25/07/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.